Analyst Price Targets — ALLO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 11:44 am | — | Bernstein | $3.85 | $3.06 | TheFly | Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein |
| April 14, 2026 11:28 am | — | Robert W. Baird | $9.00 | $3.06 | TheFly | Allogene Therapeutics price target raised to $9 from $7 at Baird |
| May 16, 2024 6:44 am | Debjit Chattopadhyay | H.C. Wainwright | $9.00 | $2.98 | StreetInsider | Allogene (ALLO) PT Lowered to $9 at H.C. Wainwright |
| May 14, 2024 7:33 am | Kalpit Patel | B.Riley Financial | $7.00 | $2.90 | StreetInsider | Allogene (ALLO) PT Lowered to $7 at B.Riley |
| June 13, 2022 11:19 pm | Jack Allen | Robert W. Baird | $11.00 | $9.74 | Pulse 2.0 | Allogene Therapeutics (ALLO) Stock Price: $11 Target From Baird |
| January 3, 2022 12:00 am | Michael Schmidt | Guggenheim | $35.00 | $15.29 | TheFly | Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim |
| December 3, 2021 12:00 am | John Newman | Canaccord Genuity | $55.00 | $17.62 | TheFly | Allogene Therapeutics clinical hold could be lifted shortly, says Canaccord |
| October 8, 2021 12:00 am | Anthony Butler | Roth Capital | $35.00 | $13.13 | TheFly | Allogene Therapeutics price target lowered to $35 from $60 at Roth Capital |
| October 8, 2021 12:00 am | Jason Gerberry | Bank of America Securities | $32.00 | $13.13 | StreetInsider | Allogene (ALLO) PT Lowered to $32 at BofA Securities |
| October 8, 2021 12:00 am | Mark Breidenbach | Oppenheimer | $40.00 | $13.13 | TheFly | Allogene Therapeutics price target lowered to $40 from $44 at Oppenheimer |
Latest News for ALLO
ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression Single Dose of ALLO-316 Produced Durable Responses in this Cohort with All Responders Progression-Free at the Time of Analysis Responses Range from 8 to 18+ Months, with Median Overall Survival Not Yet Reached Safety Profile was Manageable with Proactive…
Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in first-line large B-cell lymphoma, with a key readout in mid-2027. ALLO-329's early clinical signals in autoimmune disease, leveraging proprietary Dagger technology, set up a differentiated, scalable CAR-T platform with high-value optionality. ALLO demonstrates improving financial discipline, reducing quarterly net loss…
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Dr. David Chang, M.D., Ph.D., will transition from his role as President and Chief Executive Officer, effective June 30, 2026, following eight years…
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conferences.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALLO.
U.S. House Trading
No House trades found for ALLO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.